NEJM公布2026年11月5日新一期内容,包括retatrutide治疗成人肥胖的3期TRIUMPH-1试验。同期还刊出plozasiran治疗高甘油三酯血症与胰腺炎的3期SHASTA-3和SHASTA-4试验、povetacicept治疗IgA肾病的3期RAINIER AIS-D08试验,以及TARGET-CTCA、REACT等研究。
NEJM新一期集中刊出retatrutide减重3期与plozasiran、povetacicept等多项3期结果,可据此了解代谢与肾病领域最新证据。
New in the November 5, 2026, issue of NEJM:
Retatrutide for the Treatment of Obesity in Adults (phase 3 TRIUMPH-1 trial) https://nej.md/4ycgSHz
CT Coronary Angiography in Acute Chest Pain (TARGET-CTCA trial) https://nej.md/4wH7Yk7
Plozasiran for Hypertriglyceridemia and Pancreatitis (phase 3 SHASTA-3 and SHASTA-4 trials) https://nej.md/4iv82y3
Prevalence of Silent Atherosclerosis across Adult Life (REACT trial) https://nej.md/46gp1hP
Povetacicept in IgA Nephropathy (phase 3 RAINIER AIS-D08 trial) https://nej.md/3VWcGh6
Subscribe to NEJM for the latest medical research: https://nej.md/subscribe
来源:NEJM · x.com